• AUGUST 1, 2000

SmithKline Consumer's impressive profit growth in 2QFY01

SmithKline Beecham Consumer Healthcare (SBCH) has reported an impressive 29% in topline and a 41% jump in net profits to Rs 278 m in the 2QFY01.

(Rs m) 2QFY00 2QFY01 Change
Sales 1,620 2,084 28.6%
Other Income 51 55 7.7%
Expenditure 1,397 1,744 24.8%
Operating Profit (EBDIT) 223 341 52.8%
Operating Profit Margin (%) 13.8% 16.3%  
Interest (22) 14  
Depreciation 23 36 58.0%
Profit before Tax 273 346 26.9%
Tax 75 68 -9.9%
Profit after Tax/(Loss) 198 278 40.8%
Net profit margin (%) 12.2% 13.3%  
No. of Shares (eoy) (m) 45 45  
Diluted number of shares 45 45  
Diluted Earnings per share* 17.4 24.5  

The company's operating margins improved to 16.3% during the 2QFY01 due to effective cost control measures initiated by the company. This has resulted in a 53% increase in the operating profits. However net profit growth is comparatively lower due to increase in depreciation charge and interest cost.

The company's earnings per share of Rs 24.5, implies a P/E multiple of 18 times its 2QFY01 annualised earnings. The company's market cap to sales ratio of 2.4 times is comparatively lower than its historic 3-4 times.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407